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Abstract 
Purpose: To compare treatment plans and evaluate dosimetric characteristics of permanent cesium-131 (131Cs) vs. 
iodine-125 (125I) implants used in brain brachytherapy. 
Material and methods: Twenty-four patients with 131Cs implants from a prospective phase I/II trial were re-planned 
with 125I implants. In order to evaluate the volume of brain tissue exposed to radiation therapy (RT), the dose volume 
histogram was generated for both radioisotopes. To evaluate the dosimetric differences of the two radioisotopes we 
compared homogeneity (HI) and conformity indices (CI), and dose covering 100% (D100), 90% (D90), 80% (D80), and 
50% (D50) of the clinical target volume (CTV). 
Results: At the 100%, 90%, 80%, and 50% isodose lines, the 131Cs plans exposed less mean volume of brain tissue 
than the 125I plans (p < 0.001). The D100, D90, D80, and D50 were smaller for 131Cs (p < 0.001). The HI and CI for 131Cs vs. 
125I were 19.71 vs. 29.04 and 1.31 vs. 1.92, respectively (p < 0.001). 
Conclusions: Compared to 125I, 131Cs exposed smaller volumes of brain tissue to equivalent doses of radiation and 
delivered lower radiation doses to equivalent volumes of the CTV. 131Cs exhibited a higher HI, indicating increased 
uniformity of doses within the CTV. Lastly, 131Cs presented a CI closer to 1, indicating that the total volume receiving 
the prescription dose was closer to the desired CTV volume. These results suggest that 131Cs is dosimetrically superior 
to 125I and may explain the reason for the 0% incidence of radiation necrosis (RN) in our previously published prospec-
tive study using 131Cs. 
J Contemp Brachytherapy 2020; 12, 4: 311–316 
DOI: https://doi.org/10.5114/jcb.2020.98109
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Purpose 
Over the last decade, the rise in the length of surviv-
al for cancer patients has led to an increased incidence 
of brain metastases. Brain metastases have now been 
shown to occur in up to 40% of cancer patients and are 
the most common cause of intracranial tumors [1]. With-
out treatment, the prognosis is grim, with survival of only 
1-2 months [2]. Surgical resection of the metastases has 
been shown to increase overall survival [3]. Resection, 
however, often requires adjuvant irradiation in the form 
of stereotactic radiosurgery (SRS) or whole-brain radio-
therapy (WBRT) in order to prevent local recurrence. Due 
to WBRT’s quality of life concerns, its late toxicity pro-
file and the fact that it offers no overall survival benefit 
compared to more local therapy, recent focus has shift-
ed towards the potential of local post-resection options, 
such as SRS and intra-operative brachytherapy [4,5,6,7]. 
Brachytherapy, in particular, has received considerable 
interest as it offers some advantages even over SRS, 
namely its absence of a long-time frame that can allow 
tumor cell repopulation [4,8]. A recent study that our 
group has published has shown that surgical resection 
and intra-operative brachytherapy is more cost-effective 
compared to surgical resection and SRS in the treatment 
of brain metastasis [9]. Additionally, it is known that SRS 
does not achieve optimal local control for large (greater 
> 3 cm) and irregularly-shaped cavities [9].
Intra-operative brachytherapy implants have been 
utilized for the prevention of local recurrence in cases of 
brain metastases. Brachytherapy has historically utilized 
the iodine-125 (125I) radioisotope for both permanent and 
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temporary seed implants [10]. The commonly used radio-
isotope 125I has a T1/2 of 59.4 days and has an average en-
ergy of 28.4 keV. These physical properties make 125I con-
venient for storage, with limited shielding. The clinical 
results have revealed that although 125I has been shown 
to confer local control comparable to that of post-opera-
tive SRS, the high rates of radiation necrosis (RN) asso-
ciated with 125I brachytherapy have been criticized [11]. 
Cesium-131 (131Cs) is a relatively novel radioiso-
tope, the Food and Drug Administration cleared in 2003, 
which presents both physical and radio-biological ad-
vantages when compared to 125I brachytherapy. 131Cs has 
a shorter T1/2 of 9.69 days compared to 59.4 days for 125I. 
131Cs is more likely to be biologically efficient for the de-
struction of tumor cells, as the initial dose rate from 131Cs 
(23.9 cGy/h) is 4 times higher than that of 125I (5.8 cGy/h) 
[9,10]. Our institution was the first to report the results of 
a prospective phase I/II trial demonstrating the effective 
use of intra-operative application of 131Cs brachytherapy 
for patients with newly diagnosed brain metastases [4]. 
In that study, we reported a 0% incidence of clinical RN. 
This contrasts with the results reported by many studies 
that used permanent 125I seeds, which has been associated 
with an average RN rate of 14.4% (range, 0-26%) [12]. In 
the present study, we investigated the dosimetric profile 
of 131Cs brachytherapy compared to that of 125I in order to 
understand this disparity in RN rates. 
Material and methods 
Patient characteristics 
There were 24 patients in total, 14 females and 10 
males, with a median age of 65 years (range, 45-84 years). 
The brain metastases were located in the frontal (10), parie-
tal (7), cerebellar (4), occipital (2), and temporal (1) regions. 
The histology from the metastases was lung (16), breast (2), 
kidney (2), melanoma (2), colon (1), and cervix (1). 
Implantation procedure 
Between 2010 and 2015, following Institutional Re-
view Board approval, 24 patients were enrolled on a pro-
spective trial at the New York Presbyterian/Weill Cornell 
Medical Center, and underwent neurosurgical resection 
and intra-operative 131Cs brachytherapy for newly diag-
nosed brain metastases. The metastases were detected in 
each patient using a magnetic resonance imaging (MRI) 
or computerized tomography (CT) scan. As described 
previously [4], directly after resection, 131Cs stranded 
seeds (IsoRay, Inc., Richland, WA, USA) with an activity 
of 3-5 mCi were implanted, with a planned dose of 80 Gy 
to a 5 mm depth from the surface of the resection cavi-
ty. At the time of resection, the seeds were secured with 
Surgicel® (Ethicon, Inc., a Johnson & Johnson Company, 
Somerville, NJ, USA) to prevent seed migration and alter-
ation of dosimetry. Lastly, Tisseel® (Baxter International, 
Inc., Deerfield, IL, USA), a fibrin glue, was also placed 
within the cavity to limit cavity shrinkage and further 
prevent seed dislodgement. Post-operative CT scans (GE 
LightSpeed averaging 36.85 mGy) were performed with-
in 48 hours after surgery to determine dose distribution. 
Follow-up physical evaluation and MRIs were performed 
every 2 months thereafter. For the simulated 125I isotope 
implants, the prescribed dose was 80 Gy as well. The ex-
act implant scheme for 131Cs was used for the simulated 
125I cases. Finally, RN was detected on follow-up MRIs 
and confirmed by a combination of clinical judgement 
and further imagine including perfusion, spectroscopy, 
and positron emission tomography (PET) scans. 
Dosimetric comparison of 131Cs vs. 125I 
Dosimetric comparison was carried out for all includ-
ed 24 patients. Post-operative dosimetry plans were gen-
erated using BrachyVision (Varian Medical Systems, Palo 
Alto, CA, USA) for 131Cs seed model 131Cs Rev 2, and the 
same CT data set was re-planned with 125I seeds using 
model No 6711 (TG43). The mean air kerma strength for 
the 131Cs and 125I seeds was 2.4 U (3.768 mCi) and 0.6985 
U (0.55 mCi), respectively. The dose volume histogram 
(DVH) was generated and from it, the volume of brain 
tissue (cc) exposed to radiation at the 100%, 90%, 80%, 
and 50% isodose lines were compared for both radioiso-
topes. From the DVH, the D100, D90, D80, and D50 were 
obtained as well. Lastly, the homogeneity and confor-
mity indices were calculated for each individual patient. 
The equations used for HI and CI were as follows: 
HI = D100 – D150/D100, 
where D100 – volume enclosed by prescribed dose rate 
and D150 – volume enclosed by 1.5 times prescribed dose 
rate. 
CI = TV/CTV, 
where TV – total volume receiving prescription dose and 
CTV equals clinical target volume. 
The different mean values between 131Cs and 125I were 
compared using the Wilcoxon rank-rum test. 
Results 
Dosimetric comparison of 131Cs vs. 125I 
The median volume of resected tumor based on 
pre-operative MRI was 10.31 cc (range, 1.77-87.11 cc), in-
tra-operative measurements of the cavity revealed a me-
dian volume of 3.13 cc (range, 1.00-17.00 cc), and median 
number of seeds employed was 12 (range, 4-35 seeds). 
The clinical data from these patients resulted in 100% lo-
cal control, with median overall survival of 9.9 months, 
and 0% incidence of RN. Table 1 shows the mean volume 
of brain tissue exposed to radiation for each of the four 
isodose lines from both 131Cs and 125I. At the 100% isodose 
line, the mean volume of brain tissue exposed was 15.44 cc 
(range, 2.50-52.78 cc) and 9.84 cc (range, 1.22-32.87 cc) 
for 125I and 131Cs, respectively (p < 0.001). At the 90% 
isodose line, the mean volume exposed was 17.51 cc 
(range, 2.90-59.05 cc) and 11.31 cc (range, 1.47-37.59 cc) 
for 125I and 131Cs, respectively (p < 0.001). At the 80% iso-
dose line, the mean volume exposed was 19.96 cc (range, 
3.30-67.20 cc) and 13.61 cc (range, 1.73-43.4 cc) for 125I and 
131Cs, respectively (p < 0.001). At the 50% isodose line, 
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the mean volume exposed was 33.40 cc (range, 6.30-
109.70 cc) and 23.38 cc (range, 3.39-76.14 cc) for 125I and 
131Cs, respectively (p < 0.001). Consistently, for each isod-
ose line, the mean volume of brain tissue exposed to radi-
ation was significantly higher (on average, 52.0% higher) 
for 125I than for 131Cs. Figure 1 displays three isodose lines 
for both 125I and 131Cs seeds and superimposes them, al-
lowing the clear visualization of the contrasting volumes 
of brain tissue exposed to radiation. 
As Table 2 shows, the D100 was 64.96 Gy (range, 
46.46-10.90 Gy) and 43.99 Gy (range, 26.19-74.09 Gy) for 
125I and 131Cs, respectively (p < 0.001). The D90 was 
119.02 Gy (range, 73.44-174.36 Gy) and 78.64 Gy (range, 
40.31-136.36 Gy) for 125I and 131Cs, respectively (p < 0.001). 
Table 1. Mean volume of brain tissue exposed to 
radiation doses at different isodose lines by 131Cs 
and 125I isotopes
Isodose line Mean volume 
of brain 
tissue (cc) 
131Cs 
Mean volume 
of brain 
tissue (cc) 
125I
p-value 
100% 9.84 15.44 < 0.001 
90% 11.31 17.51 < 0.001 
80% 13.61 19.96 < 0.001 
50% 23.38 33.40 < 0.001 
Fig. 1. Axial images of a patient who underwent neurosurgical resection and intra-operative brachytherapy demonstrating vol-
ume of brain tissue exposed to radiation across multiple isodose lines for each radioisotope and superimposed comparison be-
tween 131Cs and 125I isodose lines: A) plan using 125I, B) plan using 131Cs, C) 120 Gy isodose line, D) 80 Gy isodose line, E) 40 Gy 
isodose line
A
C D E
B
 125I        131Cs  125I        131Cs 125I        131Cs
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The D80 was 141.78 Gy (range, 84.02-203.02 Gy) and 
93.09 Gy (range, 45.80-161.16 Gy) for 125I and 131Cs, re-
spectively (p < 0.001). The D50 was 206.17 Gy (range, 
113.69-289.32 Gy) and 134.79 Gy (range, 61.85-228.86 Gy) 
for 125I and 131Cs, respectively (p < 0.001). At each percent 
volume of the CTV, the dose delivered by 125I was signifi-
cantly higher (on average, 51.0% higher) than for 131Cs. 
The HI with respect to 131Cs and 125I were 0.312 
(range, 0.15-0.50) and 0.113 (range, 0-0.34), respectively 
(p < 0.001). The CI for 131Cs and 125I were 1.31 (range, 
0.71-4.12) and 1.92 (range, 0.90-3.92), respectively (p < 0.001). 
These results are summarized in Table 3. 
Discussion 
The use of permanent brachytherapy seed implants 
for the treatment of brain metastases is advantageous, 
since it can provide a treatment to a highly localized area. 
This benefit allows the physician to precisely target a de-
fined treatment volume and to avoid the surrounding tis-
sues from potential damage. Permanent brachytherapy 
offers several more advantages compared to WBRT and 
SRS. The use of post-operative SRS may require a time-
frame of 2-6 weeks after surgical resection in order to 
facilitate wound healing and stabilization of the cavity 
[4]. This delay in treatment may facilitate tumor cell re-
population. Similarly, concerns regarding the non-local-
ized nature of WBRT and its toxicity profile have likely 
contributed to the modest decrease in WBRT use. For 
instance, WBRT’s acute toxicity profile includes fatigue, 
edema, nausea, vomiting, and decreased appetite [13]. 
While these acute effects are typically resolved sponta-
neously or can be effectively treated, the late toxic effects 
of WBRT are potentially more dangerous. This includes 
potentially irreversible neurocognitive damage, leuko-
encephalopathy, and radiation necrosis [12]. Permanent 
brachytherapy also offers a quality of life benefit that 
must be considered. Both the tumor resection and sub-
sequent seed implantation occurs during one procedure, 
which is likely to increase patient satisfaction and conve-
nience. These reasons, along with its cost benefits, pro-
vide justification for the increased interest in permanent 
brachytherapy. Given this context, we believe our results 
have a widespread applicability and may inform future 
clinical decisions. 
There have been several studies reported in the liter-
ature employing the use of brachytherapy seeds for the 
treatment of brain metastases in the post-resection set-
ting. Several studies have focused on the use of tempo-
rary 125I seeds, which allow for high-dose-rate delivery; 
however, many of these studies were performed after bi-
opsy alone, and patients did not receive maximal possible 
resection. The more recent studies have used permanent 
brachytherapy seeds, of which the majority of them em-
ployed 125I. Unfortunately, most of these studies are ret-
rospective in nature, and therefore encompass a diverse 
patient cohort and may be influenced by selection bias. 
Furthermore, these studies often include patients with 
both newly diagnosed brain metastases and those with 
recurrences. Taking these factors into account, the report-
ed median survival for the treatment of newly diagnosed 
brain metastases ranges from 9.3-17.8 months and is asso-
ciated with local control rates of 60-100%, with radiation 
necrosis rates of 0-26% [11]. These data compare favor-
ably to surgical resection plus SRS in terms of both the 
median survival of 14 months as well as the local control 
rates of 85% [14]. 
The main criticism against the widespread adapta-
tion of brachytherapy for the treatment of brain metasta-
ses is the high incidence of RN that has historically been 
associated with this technique [9]. Rogers et al. reported 
23% rate of radiation necrosis when using high-dose 
temporary brachytherapy, such as the IsoRay Gliasite 
balloon [15]. Using continuous low-dose permanent 125I 
brachytherapy, Bogart et al. reported 0% rates of radia-
tion necrosis, yet only achieved 80% rate of local control 
[16]. Alternatively, Huang et al. reported 26% rate of radi-
ation necrosis, also using permanent 125I brachytherapy, 
while achieving 95% local control rate [12]. The disparity 
in results between these two series can be understood if 
attention is given to the activity and dose prescribed in 
each case. Bogart et al. employed seeds with activity of 
0.32-0.45 mCi and a cumulative dose of 80-160 Gy [15], 
while Huang et al. implanted seeds with a median activ-
ity of 0.79 mCi and delivered a median dose of 400 Gy to 
a depth of 5 mm [12]. Based on these data, Huang et al. 
concluded that decreasing both the seed activity as well 
as the prescription dose will likely result in a decrease 
of RN, while minimally impacting local control rates. 
The prospective trial for 131Cs was carefully designed to 
take into account the aforementioned factors in an attempt 
to limit the incidence of RN while maintaining local control. 
The lowered seed activity of 131Cs and our utilized dose 
prescription not only achieved a high-rate of local control 
(100%), but also resulted in zero incidences of RN [8]. 
In addition to the study design that was used when 
employing 131Cs, the physical characteristic of creating 
more lower dose gradient isodose lines to the source has 
likely contributed to its success. In this analysis, we have 
shown that even when using the same prescription dose 
Table 2. Absolute doses of radiation delivered to 
certain percent volume of CTV by 131Cs and 125I 
isotopes 
Percent volume 
of CTV 
Dose of  
radiation 
(Gy) 131Cs
Dose of 
radiation 
(Gy) 125I 
p-value 
100% (D100) 43.99 64.96 < 0.001 
90% (D90) 78.64 119.02 < 0.001 
80% (D80) 93.09 141.78 < 0.001 
50% (D50) 134.79 206.17 < 0.001 
Table 3. Comparison of homogeneity and confor-
mity indices for 131Cs and 125I
Index 131Cs 125I p-value 
Homogeneity index 0.315 0.113 < 0.001 
Conformity index 1.31 1.92 < 0.001 
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parameters as 131Cs, 125I allows for significantly higher 
amount of brain tissue being exposed to radiation. Apart 
from irradiating lower volumes of brain tissue, 131Cs also 
delivers significantly lower doses to equivalent volumes 
of CTV when compared to 125I. Additionally, the high-
er HI of 131Cs indicated more uniform dosing within the 
CTV. Lastly, the CI of 131Cs was closer to 1, indicating that 
the prescription dose was delivered more accurately to 
the desired volume of CTV. With 125I, not only was there 
less uniformity of dosing within the CTV, but the total 
volume receiving the prescription dose was also nearly 
double the desired volume of CTV. We believe that these 
factors may be particularly pertinent when looking at RN 
as an endpoint. Dagnew et al. stated that in their study, 
both patients who presented with symptomatic RN had 
lesions that exceeded 3 cm in diameter [11]. Due to the size 
of their lesions, a greater number of seeds were required 
to cover the cavity, resulting in a total radiation activity 
greater than 40 mCi. These results suggest a dose-depen-
dent risk of RN. More recently, Petr et al. reported 6% in-
cidence of RN while using permanent 125I brachytherapy 
seeds in the setting of post-resected brain metastases [17]. 
It was noted that the patients in the study had relative-
ly large metastases, and specifically all the patients that 
developed RN had lesions larger than 3 cm. Therefore, 
when compared to 125I, 131Cs limits the surrounding brain 
tissue from additional radiation, restricts dose delivery 
within the CTV, provides more uniform dosing within 
CTV, and accurately targets the desired area. These fac-
tors, in turn, may contribute to minimizing the incidences 
of RN. These characteristic of 131Cs probable allow it to be 
utilized even when dealing with cavities > 3 cm. 
Some studies have demonstrated an improved con-
trol with dose escalation [18,19,20], particularly in tumors 
receiving an equivalent dose in 2 Gy fractions (EQD2) 
> 35 Gy (α/β = 10) or biological effective dose using an 
α/β = 12 (BED 12) > 40 Gy (linear quadratic cubic model). 
There are newer prospective reports of using GammaTile 
(a 131Cs radioisotope embedded into collagen), which uti-
lizes very high doses of radiation, similar to our studies. 
The doses of 80 Gy prescribed to 5 mm depth are extract-
ed from the use of 131Cs in the prostate. Dose escalation in 
brain metastases and primary brain tumors appear prom-
ising in the radiation literature. We have utilized a con-
version from dose from low-dose-rate to high-dose-rate, 
using a dose factor of 0.54 [21]. 
It must be noted that dosimetric superiority may not 
always translate into better clinical outcomes. Prospec-
tive studies, comparing the long-term clinical outcomes 
of 131Cs and 125I, need to be performed to elucidate this 
point. Despite this, our RN levels of 0% with 131Cs are 
very encouraging and may provide a glimpse into its po-
tential long-term clinical benefits compared to 125I. It must 
also be noted that RN is a multifactorial complication and 
likely depends not only on the inherent dosimetric char-
acteristics of the radioisotope, but also on study-specific 
factors, such as the prescribed dose levels, seed activity 
levels, etc. It should also be mentioned, that because the 
strength and position of the 125I sources were not opti-
mized, it could contribute to the quality of its dosimetry. 
Another feature that impacts the incidence of RN is 
the length of time, over which the seed can deliver its in-
tended dose as well as the dynamics of the cavity during 
that time. It was recently reported that the cavity size is 
not significantly reduced in size during the 33-day peri-
od, during which 131Cs delivers 90% of its intended dose 
[22,23]. However, when dealing with an isotope, such 
as 125I, which takes 120 days to deliver the equivalent 
dose, a cavity may undergo significant shrinkage. When 
the cavity does undergo shrinkage, this means that the 
prescription dose is being delivered to a larger volume 
of surrounding tissue over time rather than the intended 
CTV volume. We believe that this fact may also contrib-
ute to the increased incidence of RN, when employing 125I 
compared to 131Cs. 
Conclusions 
In this study, we report that 131Cs permanent bra-
chytherapy for the treatment of brain metastases exposes 
lower volumes of brain tissue to radiation, provides more 
uniform dosing within CTV, and targets the desired CTV 
volume more accurately, when compared to 125I. These 
findings coupled with advantageous physical character-
istics of 131Cs, namely a shorter T1/2, shorter time of dose 
delivery, minimal volume of cavity shrinkage, and more 
compact dose distribution, provide a dosimetric superio-
rity to 125I. The results of this analysis may provide a ra-
tionale for the 0% incidence of RN, when treated with 
maximally safe neurosurgical resection and intra-opera-
tive 131Cs implantation in patients with newly resected 
brain metastases. 
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